GlassScriptPhysician profile
Julius Salamera
NPI 1548418791
$1,281.97
in general payments reported to CMS, 2019-2025
14 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2021: $213 · 2022: $133 · 2023: $151 · 2024: $107 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $497.22 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $248.93 | 2019-2025 | Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $103.65 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Janssen Products, LP | $99.95 | 2019 | |
| Abbvie INC. | $59.53 | 2025 | |
| Allergan, INC. | $48.62 | 2019 | |
| Napo Pharmaceuticals INC | $46.41 | 2019-2025 | Mytesi |
| Janssen Biotech, INC. | $44.93 | 2019 | |
| Theratechnologies INC. | $39.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Shionogi INC | $19.51 | 2025 | Fetroja |
| Pfizer INC. | $16.88 | 2023 | |
| Insmed, INC. | $16.15 | 2025 | Arikayce |
| Janssen Scientific Affairs, LLC | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Salamera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.